期刊文献+

糖尿病视网膜病变致病危险因子控制与药物干预 被引量:4

Disease risk factor control and drug intervention in diabetic retinopathy
下载PDF
导出
摘要 糖尿病视网膜病变(diabetic retinopathy,DR)是糖尿病患者常见和严重的并发症之一,也是糖尿病患者视力损害的最主要原因,其发病率一直呈现增长的趋势。随着对DR发病机制的深入研究,通过对血糖、血压及血脂危险因子的控制,以及多种药物的应用,对DR的防治取得了可喜的进展,本文就近年来对DR的危险因子控制及药物治疗的现状做一综述。 Diabetic retinopathy ( DR ) is one of the common and serious complications of diabetes, which also the main causes of visual impairment in patients with diabetes, and its incidence has been increasing. With the in- depth study of the pathogenesis of DR, through the control of risk factors including blood glucose, blood pressure and lipid, as well as the application of a variety of drugs, the prevention and cure of DR achieved a certain effect. ln this paper, we make a review of the present status and progress in recent years on the DR control risk factors and drug intervention.
作者 弓欣 徐国兴
出处 《国际眼科杂志》 CAS 2014年第12期2165-2167,共3页 International Eye Science
基金 国家自然科学基金资助项目(No.81271026) 福建省自然科学基金资助项目(No.2012J01344)~~
关键词 糖尿病视网膜病变 VEGF抑制剂 糖皮质激素 蛋白酶C抑制剂 抗氧化剂 diabetic retinopathy vascular endothelial growth factor inhibitors corticosteroids protein kinase C inhibitors antioxidants
  • 相关文献

参考文献10

二级参考文献212

共引文献88

同被引文献48

  • 1Yang W, Lu J, weng J, et aI. Prevalence of diabetes among men and women in China[J]. N EngI J Med,2010,362 (25) :1090.
  • 2Chiasson JL, Josse RG, Gomis R, et al. A carbose for pre- vention of type 2 diabetes mellitus : the STOP-NIDDM ran- domised trial [ J ]. Lancet,2002,359 ( 9323 ) :2072.
  • 3United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and mi- crovascular complications in type 2 diabetes: UKPDS 38 [ J ]. British Medical Journal, 1998,317 ( 7160 ) :703.
  • 4Ii J, Wang JJ, Chen D, et al. Systemic administ ration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 dia- betes[ J]. Exp Eye Res,2009,89( 1 ) :71.
  • 5Javadzadeh A, Ghorbanihaghjo A, Adl FH, et al. Calcium dobesilate reduces endothelin-I and high-sensitivity C-re- active protein serum levels in patients with diabetic reti- nopathy[ J]. Mol Vis,2013,19( 1 ) :62.
  • 6Becerra EM, Morescalchi F, Gandolfo F, et al. Clinical ev- idence of intravitreal triamcinolone acetonide in the man- agement of age-related macular degeneration [ J ]. Curr Drug Targets,2011,12(2) : 149.
  • 7Umesh CS, Srivastava, Ramana KV. Prevention of VEGF- induced growth and tube formation in human retinal endo- thelial cells by aldose reductase inhibition [ J ]. J Diabetes Compli-cations, 2012,26 ( 5 ) : 369.
  • 8Obmsova IG, Kador PF. Aldose reductase/polyol inhibi- tots for diabetic retinopathy [ J ]. Curr Pharm Biotechnol, 2011,12(3) :373.
  • 9Campochiaro, PA. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412[ J]. Invest. Ophthalmol. Vis. Sci ,2004,45 ( 3 ) :922.
  • 10The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe pro-liferative diabetic retinopathy in eyes with useful vision. Results of a ra ndomized trial-DiabeticReti nopathy Vitrectomy Study Re- port 3 [ J ]. Ophthalmology, 1988,95 ( 10 ) : 1307.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部